PDF(Pubmed)
Abstract：
The African pygmy hedgehog (Atelerix albiventris) is known to have a high incidence of tumor. However, investigating the tumors of this species has been constrained by the limited availability of research materials such as cell lines and genome information. In this study, we successfully established a novel cell line from a histiocytic sarcoma (HS) of an African pygmy hedgehog, allowing us to conduct a drug screening. We investigated using FDA-approved drug library screening to determine which anticancer drug this tumor cell line is sensitive to, and as a result of apoptosis experiments, bortezomib among the three proteasome inhibitors was found to induce cell death of cancer cells by significantly increasing caspase-3 cleavage (P<0.01). Thus, we elucidated that the proteasome inhibitors, particularly bortezomib, exhibit anti-tumor effects on a cell line derived from an HS in an African pygmy hedgehog through a mechanism comparable to that described in human tumors. This study reports the first characterized cell line from the African pygmy hedgehog and also highlights the potential utility of bortezomib as an anti-tumor treatment for HS in this species.
摘要：
众所周知，非洲侏儒刺猬（Atelerixalbiventris）的肿瘤发病率很高。然而,研究该物种的肿瘤一直受到有限的研究材料，如细胞系和基因组信息的限制。在这项研究中,我们成功地从非洲侏儒刺猬的组织细胞肉瘤（HS）中建立了一个新的细胞系，允许我们进行药物筛选.我们使用FDA批准的药物库筛选进行调查，以确定该肿瘤细胞系对哪种抗癌药物敏感，作为细胞凋亡实验的结果，发现三种蛋白酶体抑制剂中的硼替佐米通过显着增加caspase-3的裂解而诱导癌细胞死亡（P<0.01）。因此，我们阐明了蛋白酶体抑制剂，尤其是硼替佐米,通过与人类肿瘤中描述的机制相当的机制，对非洲侏儒刺猬中HS衍生的细胞系表现出抗肿瘤作用。这项研究报告了来自非洲侏儒刺猬的第一个特征细胞系，并强调了硼替佐米作为该物种HS抗肿瘤治疗的潜在用途。
